349 related articles for article (PubMed ID: 32701159)
21. Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism.
Metso S; Jaatinen P; Huhtala H; Auvinen A; Oksala H; Salmi J
J Clin Endocrinol Metab; 2007 Jun; 92(6):2190-6. PubMed ID: 17374710
[TBL] [Abstract][Full Text] [Related]
22. Long-term outcome of hyperthyroidism diagnosed in childhood and adolescence: a single-centre experience.
Gill DS; Greening JE; Howlett TA; Levy MJ; Shenoy SD
J Pediatr Endocrinol Metab; 2019 Feb; 32(2):151-157. PubMed ID: 30685744
[TBL] [Abstract][Full Text] [Related]
23. Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study.
Okosieme OE; Taylor PN; Evans C; Thayer D; Chai A; Khan I; Draman MS; Tennant B; Geen J; Sayers A; French R; Lazarus JH; Premawardhana LD; Dayan CM
Lancet Diabetes Endocrinol; 2019 Apr; 7(4):278-287. PubMed ID: 30827829
[TBL] [Abstract][Full Text] [Related]
24. Impact of lithium on efficacy of radioactive iodine therapy for Graves' disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal.
Bogazzi F; Giovannetti C; Fessehatsion R; Tanda ML; Campomori A; Compri E; Rossi G; Ceccarelli C; Vitti P; Pinchera A; Bartalena L; Martino E
J Clin Endocrinol Metab; 2010 Jan; 95(1):201-8. PubMed ID: 19906789
[TBL] [Abstract][Full Text] [Related]
25. Management of Graves Disease: A Review.
Burch HB; Cooper DS
JAMA; 2015 Dec; 314(23):2544-54. PubMed ID: 26670972
[TBL] [Abstract][Full Text] [Related]
26. Audit of long-term treatment outcomes of thyrotoxicosis in a single-centre virtual clinic: The utility of long-term antithyroid drugs.
Levy MJ; Reddy N; Price D; Bhake R; Bremner E; Barrowcliffe M; Kieffer V; Robinson C; Zaccardi F; Howlett TA
Clin Endocrinol (Oxf); 2022 Nov; 97(5):643-653. PubMed ID: 35274339
[TBL] [Abstract][Full Text] [Related]
27. Clinical experience of treating Graves' hyperthyroidism complicated with malignancy-The possible role of potassium iodide for avoiding the risk of thionamide-associated neutropenia.
Okamura K; Bandai S; Fujikawa M; Sato K; Kitazono T
Endocr J; 2020 Jul; 67(7):751-758. PubMed ID: 32238669
[TBL] [Abstract][Full Text] [Related]
28. The use of radioactive iodine in the management of hyperthyroidism in children.
Rivkees SA
Curr Drug Targets Immune Endocr Metabol Disord; 2001 Nov; 1(3):255-64. PubMed ID: 12477291
[TBL] [Abstract][Full Text] [Related]
29. Does thyroidectomy, radioactive iodine therapy, or antithyroid drug treatment alter reactivity of patients' T cells to epitopes of thyrotropin receptor in autoimmune thyroid diseases?
Soliman M; Kaplan E; Abdel-Latif A; Scherberg N; DeGroot LJ
J Clin Endocrinol Metab; 1995 Aug; 80(8):2312-21. PubMed ID: 7543112
[TBL] [Abstract][Full Text] [Related]
30. Radioiodine treatment of hyperthyroidism. Success rate and influence of thyrostatic medication.
Ghadban WK; Zirie MA; Al-Khateeb DA; Jayyousi AA; Mobayedh HM; El-Aloosy AS
Saudi Med J; 2003 Apr; 24(4):347-51. PubMed ID: 12754531
[TBL] [Abstract][Full Text] [Related]
31. Thyroid function and mortality in patients treated for hyperthyroidism.
Franklyn JA; Sheppard MC; Maisonneuve P
JAMA; 2005 Jul; 294(1):71-80. PubMed ID: 15998893
[TBL] [Abstract][Full Text] [Related]
32. Evaluation and Management of Children with Thyrotoxicosis.
Leung AKC; Leung AAC
Recent Pat Endocr Metab Immune Drug Discov; 2017; 11(1):22-31. PubMed ID: 29589552
[TBL] [Abstract][Full Text] [Related]
33. Definitive treatment of Graves' disease in children and adolescents.
Król A; Czarniecka A; Jarząb B
Endokrynol Pol; 2021; 72(6):661-665. PubMed ID: 34855196
[TBL] [Abstract][Full Text] [Related]
34. Managing toxic thyroid adenoma: a cost-effectiveness analysis.
Vidal-Trecan GM; Stahl JE; Durand-Zaleski I
Eur J Endocrinol; 2002 Mar; 146(3):283-94. PubMed ID: 11888833
[TBL] [Abstract][Full Text] [Related]
35. The tale of radioiodine and Graves' orbitopathy.
Ponto KA; Zang S; Kahaly GJ
Thyroid; 2010 Jul; 20(7):785-93. PubMed ID: 20578895
[TBL] [Abstract][Full Text] [Related]
36. Comparative effectiveness of therapies for Graves' hyperthyroidism: a systematic review and network meta-analysis.
Sundaresh V; Brito JP; Wang Z; Prokop LJ; Stan MN; Murad MH; Bahn RS
J Clin Endocrinol Metab; 2013 Sep; 98(9):3671-7. PubMed ID: 23824415
[TBL] [Abstract][Full Text] [Related]
37. Clinical Outcomes of Repeated Radioactive Iodine Therapy for Graves' Disease.
Kim MJ; Cho SW; Kim YA; Choi HS; Park YJ; Park DJ; Cho BY
Endocrinol Metab (Seoul); 2022 Jun; 37(3):524-532. PubMed ID: 35709827
[TBL] [Abstract][Full Text] [Related]
38. [Prevention and multimodal therapy of hyperthyroidism].
Palitzsch KD
Internist (Berl); 2008 Dec; 49(12):1428, 1430-2, 1434-6. PubMed ID: 18946641
[TBL] [Abstract][Full Text] [Related]
39. All-Cause and Cause-Specific Mortality Among Low-Risk Differentiated Thyroid Cancer Survivors in the United States.
Tran TV; Schonfeld SJ; Pasqual E; Haymart MR; Morton LM; Kitahara CM
Thyroid; 2024 Feb; 34(2):215-224. PubMed ID: 38149602
[No Abstract] [Full Text] [Related]
40. Treatment of post-radioactive iodine relapse of hyperthyroidism: comparison of long-term methimazole and radioactive iodine treatment.
Saadat N; Azizi F; Abdi H; Amouzegar A
J Endocrinol Invest; 2022 Oct; 45(10):1919-1924. PubMed ID: 35610532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
